Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.81 |
| ▸ | PRKCA | P17252 | 3/20 | 0.73 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.73 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.73 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.73 |
| ▸ | FAAH | O00519 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | SELP | P16109 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9510703 | 0.98 | DGKA (0.77) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL7570544 | 0.96 | FAAH (0.76) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL14151288 | 0.96 | DGKA (0.82) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL8781081 | 0.96 | DGKA (0.82) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL8577750 | 0.94 | DGKA (0.72) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL4435450 | 0.92 | DGKA (0.69) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL2302665 | 0.92 | LMNA (0.77) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL2701555 | 0.92 | LMNA (0.77) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL5416233 | 0.92 | LMNA (0.77) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9799388 | 0.90 | PRKCA (0.73) | DGKAPRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024057237-A1 | LIPID NANOPARTICLES | PFIZER INC. (US) | 2024-03-21 | — | — | WO | claimed |
| US-7479508-B2 | Nimesulide containing topical pharmaceutical compositions | EDKO TRADING AND REPRESENTATION COMPANY LIMITED (TR) | 2009-01-20 | — | — | US | claimed |
| US-20050020688-A1 | Nimesulide containing topical pharmaceutical compositions | EDKO PAZARLAMA TANITIM TICARET LIMITED SIRKETI (TR) | 2005-01-27 | — | — | US | claimed |
| EP-1105114-B1 | NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS | EDKO TRADING REPRESENTATION (TR) | 2003-05-28 | — | — | EP | claimed |
| JP-2002522488-A | — | — | 2002-07-23 | — | — | JP | claimed |
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | L'OREAL S.A. (FR) | 2002-04-11 | — | — | US | claimed |
| EP-1105114-A1 | NIMESULIDE CONTAINIING TOPICAL PHARMACEUTICAL COMPOSITIONS | EDKO TRADING AND REPRESENTATION COMPANY LIMITED (TR) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009117-A1 | NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS | EDKO TRADING AND REPRESENTATION COMPANY LIMITED (GB) | 2000-02-24 | — | — | WO | claimed |
| EP-3188713-B2 | METHOD OF INDUCING SATIETY | PERORA GMBH (DE) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024057237-A1 | LIPID NANOPARTICLES | PFIZER INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024040897-A1 | TRANSDERMAL PATCH OF THALIDOMIDE OR ANALOGUE THEREOF AND PREPARATION METHOD THEREFOR | 新领医药技术(深圳)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| WO-2023231359-A1 | LIPID CRYSTALLIZATION PROMOTER, PREPARATION METHOD THEREFOR AND USE THEREOF | 江南大学 | 2023-12-07 | — | — | WO | disclosed |
| US-20220202850-A1 | METHOD OF INDUCING SATIETY | PERORA GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-11311570-B2 | Method of inducing satiety | PERORA GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| WO-2000009117-A1 | NIMESULIDE CONTAINING TOPICAL PHARMACEUTICAL COMPOSITIONS | EDKO TRADING AND REPRESENTATION COMPANY LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| US-5955502-A | APPLYING TO ANIMAL OR HUMAN SKIN A BIOADHESIVE COMPOSITION COMPRISING ACTIVE OR PROTECTIVE SUBSTANCES AND FATTY ACID ESTER | GS DEVELOPMENT AB (SE) | 1999-09-21 | — | — | US | disclosed |
| EP-0752855-B1 | USE OF FATTY ACID ESTERS AS BIOADHESIVE SUBSTANCES | GS DEV AB (SE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0752855-A1 | USE OF FATTY ACID ESTERS AS BIOADHESIVE SUBSTANCES | DUMEX-ALPHARMA A/S (DK) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026715-A2 | USE OF FATTY ACID ESTERS AS BIOADHESIVE SUBSTANCES | DUMEX-ALPHARMA A/S (DK) | 1995-10-12 | — | — | WO | disclosed |
| EP-0407959-A2 | Process for producing polyol fatty acid monoesters | LION CORPORATION (JP) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | CUTA, LAGE3, MITF | DGKA 3071/4885PRKCA 1505/4885PRKCE 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.